Literature DB >> 17523780

Generalised Dermatitis Induced by Pegylated Interferon-alpha-2b in a Patient Infected with Genotype-1 Hepatitis C Virus : Presentation of a Case.

L Gallelli1, M Ferraro, G F Mauro, G De Sarro.   

Abstract

Entities:  

Year:  2005        PMID： 17523780     DOI： 10.2165/00044011-200525040-00009

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  20 in total

1.  High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus.

Authors:  S Sookoian; V Neglia; G Castaño; B Frider; M C Kien; E Chohuela
Journal:  Arch Dermatol       Date:  1999-08

2.  Cutaneous ulceration induced by interferon alfa.

Authors:  Luca Gallelli; Vincenzo Guadagnino; Benedetto Caroleo; Norma Marigliano; Giovambattista De Sarro
Journal:  Ann Pharmacother       Date:  2004-01       Impact factor: 3.154

Review 3.  [Cutaneous manifestations of rickettsiosis].

Authors:  I Noblesse; M Beylot-Barry; M S Doutre; C Beylot
Journal:  Ann Dermatol Venereol       Date:  2002-10       Impact factor: 0.777

Review 4.  Skin diseases associated with hepatitis C virus infection.

Authors:  S J Hadziyannis
Journal:  J Eur Acad Dermatol Venereol       Date:  1998-01       Impact factor: 6.166

5.  Treatment of chronic hepatitis C by interferon for longer duration than six months.

Authors:  T Poynard; V Leroy; P Mathurin; M Cohard; P Opolon; J P Zarski
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

6.  Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials.

Authors:  R L Carithers; S S Emerson
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

7.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 8.  Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?

Authors:  M L Shiffman
Journal:  Curr Gastroenterol Rep       Date:  2001-02

9.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245
View more
  2 in total

Review 1.  Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Authors:  Mark S Sulkowski; Curtis Cooper; Bela Hunyady; Jidong Jia; Pavel Ogurtsov; Markus Peck-Radosavljevic; Mitchell L Shiffman; Cihan Yurdaydin; Olav Dalgard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

2.  Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis.

Authors:  Marinella Patanè; Miriam Ciriaco; Serafina Chimirri; Francesco Ursini; Saverio Naty; Rosa Daniela Grembiale; Luca Gallelli; Giovambattista De Sarro; Emilio Russo
Journal:  Adv Pharmacol Sci       Date:  2013-05-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.